Treatment of an everolimus-responder and chemo-resistant PDX with an mTORC1/mTORC2 inhibitor (AZD2014) resulted in tumor growth inhibition, with a strong inhibition of P-S6 and an expected lack of P-AKT reactivation due to mTORC2 inhibition [23]. Here, AKT1 is linked to neoplasm.